This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. OPGN, AARD, DBVT, CRDF, QTRX, INZY, CBIO, STIM, VOR, and VMDShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), Aardvark Therapeutics (AARD), DBV Technologies (DBVT), Cardiff Oncology (CRDF), Quanterix (QTRX), Inozyme Pharma (INZY), Crescent Biopharma (CBIO), Neuronetics (STIM), Vor Biopharma (VOR), and Viemed Healthcare (VMD). These companies are all part of the "medical" sector. Miragen Therapeutics vs. Its Competitors OpGen Aardvark Therapeutics DBV Technologies Cardiff Oncology Quanterix Inozyme Pharma Crescent Biopharma Neuronetics Vor Biopharma Viemed Healthcare OpGen (NASDAQ:OPGN) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of OPGN or MGEN? 2.7% of OpGen shares are held by institutional investors. 43.8% of OpGen shares are held by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer OPGN or MGEN? In the previous week, OpGen's average media sentiment score of 0.00 equaled Miragen Therapeutics'average media sentiment score. Company Overall Sentiment OpGen Neutral Miragen Therapeutics Neutral Which has more volatility & risk, OPGN or MGEN? OpGen has a beta of -1.66, suggesting that its stock price is 266% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Is OPGN or MGEN more profitable? OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OpGen-1,140.36% N/A -287.58% Miragen Therapeutics -1,393.50%-141.66%-88.74% Which has better valuation & earnings, OPGN or MGEN? OpGen has higher earnings, but lower revenue than Miragen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpGen$2.67M0.15-$32.67MN/AN/AMiragen Therapeutics$4.46M15.12-$41.87M-$20.09-0.86 SummaryOpGen beats Miragen Therapeutics on 5 of the 9 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.45M$812K$5.60B$9.56BDividend YieldN/AN/A4.70%4.05%P/E Ratio-1.62N/A28.2120.13Price / Sales15.120.99429.9386.78Price / CashN/AN/A25.1828.40Price / Book2.550.118.465.81Net Income-$41.87M-$27.68M$3.25B$259.24M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$17.26-0.1%N/A+3.7%$67.45M$4.46M-1.6245High Trading VolumeOPGNOpGenN/A$4.70flatN/A-98.7%$47.32M$2.67M0.00100Gap DownAARDAardvark TherapeuticsN/A$13.75+14.6%$33.00+140.0%N/A$260.35MN/A0.0018DBVTDBV Technologies3.914 of 5 stars$9.28-2.3%$14.75+58.9%+111.3%$260.32M$4.15M-1.8980Gap UpCRDFCardiff Oncology1.6445 of 5 stars$3.78-3.3%$11.70+209.5%+59.4%$260.12M$587K-4.1120News CoveragePositive NewsQTRXQuanterix2.2255 of 5 stars$5.51+6.4%$13.50+145.0%-58.3%$258.76M$137.42M-4.24460News CoveragePositive NewsINZYInozyme Pharma2.7771 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750Upcoming EarningsCBIOCrescent Biopharma3.4188 of 5 stars$13.04-1.2%$25.67+96.8%N/A$258.06MN/A-0.2850Positive NewsSTIMNeuronetics1.6329 of 5 stars$4.22+8.8%$5.50+30.3%+139.2%$256.52M$74.89M-3.22180News CoveragePositive NewsUpcoming EarningsVORVor Biopharma3.6997 of 5 stars$2.05flat$5.63+174.6%+151.6%$256.17MN/A-1.24140VMDViemed Healthcare1.3782 of 5 stars$6.50+0.5%N/A-16.0%$255.72M$224.26M21.671,179 Related Companies and Tools Related Companies OpGen Alternatives Aardvark Therapeutics Alternatives DBV Technologies Alternatives Cardiff Oncology Alternatives Quanterix Alternatives Inozyme Pharma Alternatives Crescent Biopharma Alternatives Neuronetics Alternatives Vor Biopharma Alternatives Viemed Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
